Alexander Spira, MD, PhD, FACP, discusses osimertinib-relapsed disease and its sensitivity to EGFR or MET inhibition.
Alexander Spira, MD, PhD, FACP, director of the Virginia Cancer Specialists Research Institute, discusses osimertinib (Tagrisso)-relapsed disease and its sensitivity to EGFR or MET inhibition.
Currently, there are not many treatment options for patients with relapsed/refractory NSCLC that harbors an EGFR mutation. In an attempt to develop new therapies and combinations, investigators started the phase 1 CHRYSALIS-2 trial (NCT04077463).
In the phase 1 CHRYSALIS-2 trial, investigators evaluated the combination of amivantamab-vmjw (Rybrevant) and lazertinib (Leclaza) for patients with relapsed or refractory EGFR-mutant NSCLC. Here, Spira explains the methods and design of the study, which had its data presented at the 2022 IASLC World Conference on Lung Cancer.
0:08 | Osimertinib- relapsed disease has been a tough cancer [to treat] just because there's not a clear standard of care. We usually give people just chemotherapy alone, which is really the only standard of care, or dealing with oligo radiation, but we obviously need to do a better job. The focus has been on new classes of EGFR inhibitors because of a couple of reasons. One is that the mechanism of resistance is multifold. The most common things that we see is something called C797S or MET amplification or even other mutations. The concept of drugs including lazertinib, which is a [tyrosine kinase inhibitor], and amivantamab, which is an antibody, helps attack it on multiple fronts.
0:49 | The CHRYSALIS-2 study is a very broad study. The CHRYSALIS-2 study has multiple different cohorts combining both amivantamab and lazertinib alone in several different patient patient populations, as well as with chemo, so it has multiple different aspects of the clinical study. But it is really looking at patients who progressed on osimertinib and treating them with this combination afterwards to assess response.